Noa Gordon

810 total citations
41 papers, 563 citations indexed

About

Noa Gordon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Noa Gordon has authored 41 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Noa Gordon's work include Economic and Financial Impacts of Cancer (8 papers), Gastric Cancer Management and Outcomes (8 papers) and Colorectal Cancer Surgical Treatments (6 papers). Noa Gordon is often cited by papers focused on Economic and Financial Impacts of Cancer (8 papers), Gastric Cancer Management and Outcomes (8 papers) and Colorectal Cancer Surgical Treatments (6 papers). Noa Gordon collaborates with scholars based in Israel, United States and United Kingdom. Noa Gordon's co-authors include Daniel A. Goldstein, Salomon M. Stemmer, Assaf Moore, Michal Sarfaty, Moshe Leshno, Dan Greenberg, Eli Rosenbaum, Victoria Neiman, Miri Yemini and Yulia Kundel and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Noa Gordon

40 papers receiving 555 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Noa Gordon Israel 12 236 169 143 134 63 41 563
Timothy A. Lin United States 12 131 0.6× 118 0.7× 130 0.9× 84 0.6× 18 0.3× 60 561
Dayssy A. Diaz United States 12 151 0.6× 114 0.7× 23 0.2× 118 0.9× 45 0.7× 47 388
W.K. Evans Canada 10 253 1.1× 200 1.2× 160 1.1× 62 0.5× 17 0.3× 31 538
Alan Paciorek United States 13 239 1.0× 311 1.8× 40 0.3× 55 0.4× 18 0.3× 45 594
Temidayo Fadelu United States 11 359 1.5× 78 0.5× 109 0.8× 51 0.4× 24 0.4× 36 611
E. Greer Gay United States 7 247 1.0× 322 1.9× 54 0.4× 179 1.3× 13 0.2× 10 680
Mei‐Chin Hsieh United States 16 476 2.0× 318 1.9× 86 0.6× 164 1.2× 11 0.2× 64 832
Niels Neymark Belgium 11 352 1.5× 397 2.3× 92 0.6× 112 0.8× 17 0.3× 21 640
J.W.H. Leer Netherlands 11 154 0.7× 252 1.5× 66 0.5× 68 0.5× 24 0.4× 16 601
Nathan Sheets United States 18 175 0.7× 371 2.2× 126 0.9× 269 2.0× 10 0.2× 44 926

Countries citing papers authored by Noa Gordon

Since Specialization
Citations

This map shows the geographic impact of Noa Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noa Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noa Gordon more than expected).

Fields of papers citing papers by Noa Gordon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noa Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noa Gordon. The network helps show where Noa Gordon may publish in the future.

Co-authorship network of co-authors of Noa Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Noa Gordon. A scholar is included among the top collaborators of Noa Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noa Gordon. Noa Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Limon, Dror, Alexandra Amiel, Noa Gordon, et al.. (2024). A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor. Neuro-Oncology Advances. 6(1). vdae154–vdae154. 1 indexed citations
3.
Brenner, Baruch, Yulia Kundel, Noa Gordon, et al.. (2022). Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab for locally advanced esophageal cancer using 18F-FDG PET-CT imaging: a prospective cohort study. Journal of Gastrointestinal Oncology. 13(6). 2721–2735. 1 indexed citations
4.
Moore, Assaf, Shlomit Yust‐Katz, Noa Gordon, et al.. (2021). Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors. Journal of the Neurological Sciences. 427. 117556–117556. 7 indexed citations
5.
Gordon, Noa, Daniel A. Goldstein, Boaz Tadmor, Salomon M. Stemmer, & Dan Greenberg. (2021). Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System. Frontiers in Pharmacology. 12. 754390–754390. 4 indexed citations
6.
7.
Limon, Dror, Noa Gordon, Lior H. Katz, et al.. (2018). Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. Journal of Neuro-Oncology. 138(2). 315–320. 10 indexed citations
8.
Sarfaty, Michal, Peter Hall, Kelvin Chan, et al.. (2018). Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. European Urology. 74(1). 57–62. 49 indexed citations
9.
Moore, Assaf, Michal Cohen‐Naftaly, Anna Tobar, et al.. (2017). Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiation Oncology. 12(1). 163–163. 55 indexed citations
10.
Sarfaty, Michal, Moshe Leshno, Noa Gordon, et al.. (2017). Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. European Urology. 73(4). 628–634. 58 indexed citations
11.
Sarfaty, Michal, Assaf Moore, Ofer Purim, et al.. (2017). Esophageal Cancer in Israel has Unique Clinico-Pathological Features: A Retrospective Study. Journal of Cancer. 8(13). 2417–2423. 2 indexed citations
12.
Brenner, Baruch, Michal Sarfaty, Ofer Purim, et al.. (2016). A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer. PLoS ONE. 11(7). e0157548–e0157548. 4 indexed citations
13.
Moore, Assaf, Michal Cohen‐Naftaly, Ofer Benjaminov, et al.. (2016). Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. Journal of Cancer. 7(8). 883–889. 4 indexed citations
14.
Yemini, Miri & Noa Gordon. (2015). Media representations of national and international standardized testing in the Israeli education system. Discourse Studies in the Cultural Politics of Education. 38(2). 262–276. 26 indexed citations
15.
Gordon, Noa, et al.. (2015). A Search for Ribonucleic Antiterminator Sites in Bacterial Genomes: Not Only Antitermination. Microbial Physiology. 25(2-3). 143–153. 2 indexed citations
16.
Wasserberg, Nir, Ofer Purim, Yulia Kundel, et al.. (2015). Early Postoperative 18F-FDG PET/CT in High-Risk Stage III Colorectal Cancer. Clinical Nuclear Medicine. 40(4). e222–e227. 6 indexed citations
17.
Purim, Ofer, Yulia Kundel, Efraim Idelevich, et al.. (2013). Weekly docetaxel and cisplatin with capecitabine and bevacizumab (AVDCX) in patients with advanced esophagogastric cancer: Results of a phase Ib/II study.. Journal of Clinical Oncology. 31(15_suppl). e15078–e15078. 2 indexed citations
18.
Purim, Ofer, Yulia Kundel, Ronen Brenner, et al.. (2012). The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer. Anti-Cancer Drugs. 23(3). 313–320. 6 indexed citations
19.
Kundel, Yulia, Ofer Purim, Hanna Bernstine, et al.. (2012). Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study. Radiation Oncology. 7(1). 124–124. 27 indexed citations
20.
Stellato, T A, et al.. (1988). Splenectomy and the induction of cancer of the colon in rats.. PubMed. 45(1). 12–5. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy A. Lin Breakdown of academic impact, for papers by Dayssy A. Diaz Breakdown of academic impact, for papers by W.K. Evans Breakdown of academic impact, for papers by Alan Paciorek Breakdown of academic impact, for papers by Temidayo Fadelu Breakdown of academic impact, for papers by E. Greer Gay Breakdown of academic impact, for papers by Mei‐Chin Hsieh Breakdown of academic impact, for papers by Niels Neymark Breakdown of academic impact, for papers by J.W.H. Leer Breakdown of academic impact, for papers by Nathan Sheets
Rankless by CCL
2026